91396-13-3Relevant articles and documents
CHEMICAL COMPOUNDS
-
Paragraph 0584-0586, (2021/01/23)
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.
Buchwald-Hartwig reactions in water using surfactants
Salomé, Christophe,Wagner, Patrick,Bollenbach, Maud,Bihel, Frédéric,Bourguignon, Jean-Jacques,Schmitt, Martine
, p. 3413 - 3421 (2014/05/06)
Examination of the scope and limitation of the Buchwald-Hartwig cross-coupling reaction in micellar medium is reported. An array of aryl or heteroaryl halides were coupled to diverse nitrogen coupling partners using a combination of [(allyl)PdCl]2 and cBRIDP to afford the corresponding products in moderate to excellent yields. 30 examples are reported, including polar solid and fairly water-soluble organic substrates/reagents.